Feb 7 (Reuters) – Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill. (Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Fabian Hamacher, Yi-Chin Lee and Ann Wang TAIPEI, June 27 (Reuters) - Mandopop megastar…
By Fabian Hamacher, Yi-Chin Lee and Ann Wang TAIPEI, June 27 (Reuters) - Mandopop megastar…
New Delhi [India], June 26: Reinforcing its commitment to environmental sustainability and responsible corporate citizenship, KAI…
Mumbai (Maharashtra) [India], June 26: The finance sector is going through unprecedented changes right now;…
Inside the cockpit of a Piper Archer DX, at Chimes Aviation Academy. Gurugram (Haryana) [India],…
Kathmandu [Nepal], June 26: Only a few professionals can excel at both clinical practice and…